The take-home message from Thomson Reuters Recap’s analysis of 2013 biopharma dealmaking was no surprise: It was a very good year across the board for initial public offerings (IPO), M&A and licensing agreements. However, the analysis also suggested that pharmas and biotechs are beginning to dance to a slightly different beat.